Volume 64, Issue 2, Pages (August 2003)

Slides:



Advertisements
Similar presentations
Volume 66, Issue 4, Pages (October 2004)
Advertisements

Home care assistance and the utilization of peritoneal dialysis
Volume 61, Issue 2, Pages (August 2014)
Volume 62, Issue 6, Pages (December 2002)
Volume 62, Issue 2, Pages (August 2002)
Treatment of acute renal failure
Volume 55, Issue 6, Pages (June 1999)
Volume 54, Issue 2, Pages (August 1998)
Volume 64, Issue 6, Pages (December 2003)
From: Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate.
Volume 64, Issue 4, Pages (October 2003)
Volume 70, Issue 3, Pages (August 2006)
Diagnosis and Management of Chronic Kidney Disease
Sushrut S. Waikar, Venkata S. Sabbisetti, Joseph V. Bonventre 
Tuberculosis and tubulointerstitial nephritis: an intriguing puzzle
Volume 59, Issue 5, Pages (May 2001)
Volume 67, Issue 5, Pages (May 2005)
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.
Prehypertension and chronic kidney disease: the ox or the plow?
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 88, Issue 2, Pages (August 2015)
Better nephrology for mice—and man
Volume 77, Issue 8, Pages (April 2010)
Volume 77, Issue 1, Pages 5-6 (January 2010)
How to interpret the eGFR in patients with small body surface area
Volume 62, Issue 6, Pages (December 2002)
Treatment of acute renal failure
Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1  Lyndsay S. Baines, John T. Joseph,
Volume 78, Issue 7, Pages (October 2010)
Volume 65, Issue 2, Pages (February 2004)
Volume 61, Issue 4, Pages (April 2002)
Volume 60, Issue 4, Pages (October 2001)
Volume 70, Issue 1, Pages (July 2006)
Volume 76, Issue 3, Pages (August 2009)
The third World Kidney Day: Looking back and thinking forward
Volume 66, Issue 2, Pages (August 2004)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske 
Volume 73, Issue 5, Pages (March 2008)
Methods for guideline development
Volume 61, Issue 4, Pages (April 2002)
Lesley A. Stevens, MD, MS, Nicholas Stoycheff, MD 
Volume 56, Issue 2, Pages (August 1999)
Volume 64, Issue 6, Pages (December 2003)
Volume 57, Issue 1, Pages (January 2000)
Recapitulation of phylogeny by ontogeny in nephrology
Volume 80, Issue 3, Pages (August 2011)
Volume 74, Issue 5, Pages (September 2008)
Douglas G Matsell, Colin T White  Kidney International 
Volume 58, Issue 5, Pages (November 2000)
Volume 79, Issue 4, Pages (February 2011)
Volume 60, Issue 3, Pages (September 2001)
Volume 60, Issue 1, Pages (July 2001)
Blood lead and chronic kidney disease in the general United States population: Results from NHANES III  Paul Muntner, Jiang He, Suma Vupputuri, Josef.
Volume 62, Issue 2, Pages (August 2002)
Volume 83, Issue 3, Pages (March 2013)
Volume 80, Issue 10, Pages (November 2011)
Volume 80, Issue 10, Pages (November 2011)
Volume 89, Issue 5, Pages (May 2016)
Volume 55, Issue 3, Pages (March 1999)
Volume 55, Issue 6, Pages (June 1999)
Volume 65, Issue 1, Pages (January 2004)
Volume 58, Issue 2, Pages (August 2000)
Volume 66, Issue 4, Pages (October 2004)
Volume 58, Issue 5, Pages (November 2000)
Podocytopenia and disease severity in IgA nephropathy
A. Lauschke, U.K.M. Teichgräber, U. Frei, K.-U. Eckardt 
The Ebf1 knockout mouse and glomerular maturation
Volume 79, Issue 10, Pages (May 2011)
Presentation transcript:

Volume 64, Issue 2, Pages 593-602 (August 2003) A randomized, placebo-controlled trial of IGF-1 for delayed graft function: A human model to study postischemic ARF  Michelle A. Hladunewich, Geraldine Corrigan, Geraldine C. Derby, Deepa Ramaswamy, Neeraja Kambham, John D. Scandling, Bryan D. Myers  Kidney International  Volume 64, Issue 2, Pages 593-602 (August 2003) DOI: 10.1046/j.1523-1755.2003.00100.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Patient population graphic summary of patients recruited, randomized, and analyzed. CrCl is creatinine clearance. Kidney International 2003 64, 593-602DOI: (10.1046/j.1523-1755.2003.00100.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Serum insulin-like growth factor (IGF-1) levels. Serum IGF-1 levels at baseline prior to randomization and on day 3 posttransplantation in the placebo and IGF-1 treatment groups. *P < 0.0001 in IGF-1 group on day 3 compared to day 0. Kidney International 2003 64, 593-602DOI: (10.1046/j.1523-1755.2003.00100.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Inulin clearance on day 7 posttransplantation. A scattergram of individual inulin clearances on day 7. No significant difference between the group means was detected (19 ± 19mL/min in the placebo group versus 21 ± 22mL/min in the IGF-1 group; P = 0.67). Kidney International 2003 64, 593-602DOI: (10.1046/j.1523-1755.2003.00100.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Creatinine versus inulin clearance. The creatinine clearance is plotted as a function of the inulin clearance. Notice that when the glomerular filtration rate (GFR) is < 20mL/min, the two measures cluster around the line of identity (solid line). However, as the proximal tubule recovers and GFR improves, creatinine clearance typically overestimates the corresponding inulin clearance due to the return of creatinine secretion. Kidney International 2003 64, 593-602DOI: (10.1046/j.1523-1755.2003.00100.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 5 Bland and Altman measure of agreement between clearances. Displayed is the measure of agreement between two methods utilized to determine the glomerular filtration rate (GFR), creatinine clearance versus the gold standard, inulin clearance. At or below 20mL/min of GFR, as determined by inulin clearance, the creatinine clearance approximates the gold standard well with a bias of only +0.3mL/min (solid line) and an interval of agreement of -11 to +11mL/min (dashed line). Kidney International 2003 64, 593-602DOI: (10.1046/j.1523-1755.2003.00100.x) Copyright © 2003 International Society of Nephrology Terms and Conditions